Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]APN-1607 Uptake in Alzheimer's Disease Dementia
NCT05043675Phase 1Unknown
- Sponsor
- Nanjing First Hospital
- Start
- Sep 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of florzolotau in Alzheimer's disease (AD), sponsored by Nanjing First Hospital. Primary endpoint: Assessment of [18F]APN-1607 Uptake Patterns by Regional SUV Values at 36 months. Status: unknown.
02
Drugs
florzolotau
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05043675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05043675.